Co-PSMA data published in the European Urology journal
- Written by PR Newswire
![]() |
SYDNEY, March 31, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results from the Co-PSMA (NCT06907641)[1] investigator-initiated...
Read more: Co-PSMA data published in the European Urology journal















